Aberrant wnt signaling caused by mutations in CTNNB1 occurs in about 15% of Wilms tumors, and these mutations appear to be dependent on the concomitant mutational inactivation of the zinc-finger protein WT1. Nuclear bcatenin protein, a substitute marker of active wnt signaling, has been detected in an even higher proportion (.50%) of Wilms tumors, suggesting alternative genetic pathways leading to b-catenin activation. Thus, targeting wnt signaling may become an important future therapeutic strategy in Wilms tumor patients. Currently, chemically induced rat nephroblastomas provide the only available rodent model for this tumor. To determine the contribution of active wnt signaling in this model, we investigated 24 chemically induced rat nephroblastomas for b-catenin protein expression and for Ctnnb1 and WT1 mutations. Immunohistochemistry showed focal strong nuclear accumulation of b-catenin protein in 18 of 24 tumors, although in a heterogenous pattern. Blastemal and mesenchymal compartments displayed nuclear-positive cells more frequently than areas of epithelial differentiation. Interestingly, we found no mutation of exon 3 of Ctnnb1 and no mutation within the zinc-finger region of WT1 in any of the 24 tumors analyzed. In conclusion, our findings suggest activation of wnt signaling in the majority (63%) of chemically induced rat nephroblastomas. Nuclear expression of b-catenin in the absence of Ctnnb1 mutations implies, however, alternate mutational targets in rat nephroblastomas.
INTRODUCTION
Wilms tumor is the most common pediatric kidney cancer and among the most common childhood malignancies in Europe and North America [1, 2] . One of 10 000 children is affected. Most Wilms tumors occur sporadically and are unilateral, but there are also a few cases (1%) with a family history that are often bilateral and manifest earlier [3] [4] [5] . Chemotherapy, surgery, and radiation in advanced stages of disease are the current therapeutic strategies and result in the overall cure of about 85% of patients. However, because of toxicity and long-term side effects, the development of novel improved therapeutic approaches is still warranted.
Wilms tumors are thought to arise from metanephric blastemal cells that normally differentiate into the epithelial components of the mature nephron. Wilms tumors recapitulate metanephrogenesis and have a histologic architecture showing varying proportions of epithelial, mesenchymal, and blastemal components. Some Wilms tumors even show heterologous cartilaginous or rhabdomyoblastoid differentiation.
Little is known about the genetic basis of Wilms tumor development. Up to 25% of human nephroblastomas may harbor inactivating mutations of the Wilms tumor suppressor gene WT1 [6] [7] [8] , about 15% of cases show mutations in CTNNB1 [9, 10] , the gene encoding bcatenin, and about 30% of Wilms tumors show functional inactivation of WTX [11] . Interestingly, some remarkable associations between these different mutations have been found. Maiti and colleagues [10] have shown that Wilms tumors with CTNNB1 mutations almost invariably have concomitant mutations of WT1, whereas some tumors have WT1 mutations without mutations in CTNNB1. Rivera and others [11] have shown that WTX is preferentially inactivated in those tumors lacking both CTNNB1 and WT1 mutations but that WTX inactivation itself leads indirectly to activation of b-catenin. From these studies, activation of b-catenin by either direct or indirect means emerges as a central mechanism of Wilms tumorigenesis.
Beta-catenin is the main effector molecule of the wnt signaling pathway and, in the absence of wnt ligands, is phosphorylated by glycogen synthase kinase 3b, APC, and axin, which leads to b-catenin's rapid ubiquitinmediated degradation [12] [13] [14] . Activation of the wnt signaling pathway is initiated by binding of wnt proteins to their receptors on the cell surface, which trigger the intracellular inhibition of b-catenin phosphorylation. This in turn leads to accumulation and nuclear translocation of b-catenin protein, which it interacts with members of the Lef-1/TCF family. As heterodimeric transcription factors, they cause transcriptional upregulation of specific target genes, such as cyclin D1 and c-myc [15, 16] .
Although the wnt signaling pathway is a prominent target for the development of novel anticancer drugs [17] [18] [19] [20] [21] [22] [23] , translational research in Wilms tumors is hampered by the fact that the incidence of Wilms tumors is relatively low and that preclinical animal models and in vitro models are rare. The rat, however, offers a unique opportunity in the study of nephroblastoma. Rat strains, such as Noble [24] and Sprague-Dawley [25] , are predisposed to spontaneous nephroblastoma development and can be induced with direct alkylating agents, such as N-ethylnitrosourea (ENU), or with nitrosamines to form nephroblastomas at high incidence with transplacental or neonatal exposures [26, 27] . These neoplasms show a triphasic histotype typical of Wilms tumors with favorable histology.
The aim of our study was to characterize this rat model of chemically induced nephroblastomas for alterations affecting the wnt signaling pathway.
METHODS

Tumor samples
All tumor induction studies were performed in accordance with an animal study protocol approved by the National Institutes of Health Animal Care and Use Committee. All tumors were histologically classified after hematoxylin and eosin staining of 2-mm thick sections.
Male and female Noble rats were obtained from Charles River (Kingston, NY, USA) at 6 to 8 weeks of age. Dr G. Muschik (Chemical Synthesis and Analysis Laboratory, Sciences Applications International Corporation, Frederick Cancer Research and Development Center, Frederick, MD, USA) synthesized the N-ethylnitrosourea, which was stored at 220uC and was dissolved and diluted in saline just before use. Female and male Noble rats were paired overnight, and the females were examined the next morning (O-dpc) for vaginal plugs. Pregnancy was confirmed by palpation 10 days later. At 17 days post coitum, the pregnant rats received an intraperitoneal injection of 0.5 mmol/kg body weight ENU. They were allowed to deliver normally and to nurse their offspring, which were weaned at 4 weeks of age. Rats were killed when tumors became palpable or the animals became moribund. Kidneys were either snap frozen in liquid nitrogen or fixed in 10% buffered formalin and embedded in paraffin.
Methyl(methoxymethyl)nitrosamine (DMN-OMe) was synthesized according to the method of Eiter and others [28] . Neonatal F344/NCr rats received a single intraperitoneal injection of DMN-OMe (4.0 mmol/kg of body weight) in phosphate-buffered saline (pH 7.0) within 48 hours after birth. Large palpable renal masses were excised from killed animals and fixed for histology or frozen at 270uC for DNA extraction.
Immunohistochemistry
Immunostaining with antibodies against b-catenin was performed on paraffin-embedded tissue (2-mm thick sections). Antigen retrieval was achieved by microwave treatment twice in 10 mM citrate buffer (pH 6.0) for 5 minutes. Endogenous peroxidase was quenched with methanol and hydrogen peroxide. Primary b-catenin antibody (C19220, Transduction Laboratories, Lexington, KY, USA) was diluted 1:200 and incubated over night (4uC). A standard peroxidase-antiperoxidase protocol was used for visualization, with diaminobenzidine as chromogen.
Staining distribution within the tumors was noted, and within positive areas, the subcellular localization was carefully evaluated and noted as membranous, cytoplasmic, or nuclear. In addition, the distribution of staining among tissue compartments was noted and the proportion of stained cells scored in percent of tumor cells. For focal staining, the percentage of tumor cells per positive tumor area was indicated. Staining intensity was graded semiquantitatively from negative (2) to weakly (+), moderately (++), and strongly (+++) positive.
Cell culture
Cell lines used in the reporter gene assays were CC531 (rat colon carcinoma cell line harboring an activating mutation of Ctnnb1 [29] ), ENU-T1 (rat nephroblastoma cell line with wild-type Ctnnb1 [30] ), HCT116 (human colon carcinoma cell line harboring an activating mutation of Ctnnb1 [31] ), and 293T (human embryonic kidney-derived cell line with wild-type Ctnnb1 [32] ). HCT116 and 293T cells were kindly provided by Dr S. Dihlmann, University of Heidelberg, Germany. The ENU-T1 cells were provided by Y. Nagashima, Department of Pathology, Yokohama City University, Yokohama, Japan.
All cells were cultured under sterile conditions in RPMI 1640 medium supplemented with 10% (v/v) fetal calf serum, 100 U/mL penicillin, and 100 mg/mL streptomycin at 37uC in a humidified atmosphere of 5% carbon dioxide. All cell culture reagents by Gibco BRL, Karlsruhe, Germany.
TOPflash/FOPflash transfection assays
For the TOPflash/FOPflash reporter assays (Upstate Biotechnology, Lake Placid, NY, USA), 5 3 10 5 cells were seeded per well the day before transfection. Transfection was performed with a Qiagen Effectene Transfection Kit (Hilden, Germany). Cells were transfected with 1 mg vector DNA (pTOPflash or pFOPflash) and 0.2 mg pRSV-lacZ as a normalization vector [33] . After 24 hours of incubation, cells were harvested and lysed for standard luciferase assay (Promega GmbH, Mannheim, Germany) measured on a Sirius Luminometer (V2.2). For normalization, a standard galactosidase assay (Promega) was used. All transient transfection experiments were performed in triplicate and repeated one time.
To normalize the data of the different cell lines, the relative light counts per second measured in the luminometer were correlated with the absorption measured with the galactosidase assay at 405 nm.
To derive the fold activation, the arithmetic mean was calculated from all transfections and the TOPflash mean was divided through the FOPflash mean. Standard deviation was calculated from the single TOPflash/ FOPflash ratios against the mean ratio of all transfections.
DNA purification
Genomic DNA was extracted from snap-frozen tumor tissue according to Sukumar and colleagues [34] or from paraffinembedded tumor tissues after microdissection to remove contaminating normal tissue. Tumor tissue from 3 to 5 6-mm-thick sections stained with hematoxylin and eosin was directly transferred into 180 mL of tissue lysis buffer from the QIAmp DNA Mini Kit (Qiagen) and incubated at 57uC overnight. The procedure of DNA purification was according to the protocol supplied with the kit. The integrity of the purified DNA was checked on a 0.8% agarose gel.
Polymerase chain reaction amplification
Polymerase chain reaction (PCR) was performed according to Koesters and others [29] . Amplification was performed for 35 cycles in a reaction containing 2 mM magnesium chloride and 1U Platinum-Taq Polymerase (Life Technologies, Rockville, MD, USA). Cycling conditions were as follows: initial denaturation for 5 minutes at 94uC, 35 cycles of denaturation for 30 seconds at 94uC, 30 seconds of annealing at 55u-65uC, and 30 seconds of elongation at 72C, followed by a final step of elongation for 7 minutes at 72uC.
The PCR primers for amplification of Ctnnb1 exon 3 were as follows:
RNbcat-fwd1: GCTGACCTGATGGAGTTGGA-39 RNbcat-rev1: GCTACTTGCTCTTGCGTGAA-39
The PCR primers for amplification of WT1 exons 7-10 were as follows:
RN-wt1E7-fwd1: TTTCAGTGTTCAGTTTCC-CATG-39 RN-wt1E7-rev1: GTGGCCTGAACTTTCAAAG-TG-39 RN-wt1E8-fwd1: TCCCAGAAGTCTACAGCAC-TACC-39 RN-wt1E8-rev1: GGTAGATCACCCTCTTGTC-TGTG-39 RN-wt1E9-fwd1: GAAGCATGAGGTCCCAGTA-GAC-39 RN-wt1E9-rev1: AGCCATTCTCTGAATGGATT-CTC-39 RN-wt1E10-fwd1: GAGCCAGTTGGCTAGCT-TAGG-39 RN-wt1E10-rev1: AAGGAAAAGAGGAAAGT-CAGGG-39
Polymerase chain reaction fragments were purified using a High Pure PCR Purification Kit (Roche Diagnostics, Basel, Switzerland), essentially as recommended by the manufacturer.
DNA sequencing
Sequencing reactions were set up using 30 ng of purified PCR product and 10 pmol of sequencing primer in a total reaction volume of 10 mL following a dye terminator protocol (Big Dye, Applied Biosystems, Darmstadt, Germany). The sequencing reactions were run on an ABI Prism 310 DNA Sequencer (Applied Biosystems). The sequencing primers were as follows:
Rnbcat-rev2: CTTGCTCCCACTCATAAAGG-39 RN-wt1E7-fwd2: TCACATAGGGCACAAGGT-CTC-39 RN-wt1E8-fwd2: GGATCCCTTCATCTGCATT-TAG-39 RN-wt1E9-fwd2: CTGGCTGATGTGAAAGA-TATGC-39 RN-wt1E10-fwd2: ATAGTTGAACCTGTGCC-CAGTC-39
RESULTS
Tumor pathology
In this study, we analyzed a total number of 24 chemically induced rat nephroblastomas. Seventeen of NUCLEAR b-CATENIN IN RAT NEPHROBLASTOMAS the analyzed tumors were primary nephroblastomas (15 induced with ENU and 2 induced with DMN-OMe), whereas 7 of the analyzed tumors were syngeneic transplants of ENU-induced primary nephroblastomas. All tumors were composed of blastemal, mesenchymal, and epithelial components as is typically seen in triphasic Wilms tumor. The different histologic subcompartments were, however, unevenly distributed. Most of the tumors presented with a mainly undifferentiated blastemal component. Some of the tumors showed rhabdomyoblastoid differentiation, which is also commonly seen in Wilms tumors. One nephroblastoma showed diffuse anaplasia (Table 1) .
Immunohistochemistry
The b-catenin immunophenotype of all tumors and of normal rat kidney was assessed by immunohistochemistry. All parameters involved in the b-catenin phenotype were diligently analyzed. Immunohistochemical staining for b-catenin was evaluated according to subcellular localization and staining intensity, as well as percent of cells expressing b-catenin.
In normal peritumoral rat kidney, b-catenin protein was mainly localized to tubular epithelial membranes. The strongest membranous b-catenin staining was found laterally and basally. Additionally, tubular epithelial cells also showed weak cytosolic b-catenin staining. Distal tubules always showed stronger membranous and cytosolic immunoreactivity than proximal tubules. Nuclear staining was never observed in normal rat kidney. None of the nonepithelial components of the kidney, such as the capillary loops of the glomeruli or the stroma or interstitial cells, showed any b-catenin protein expression (Fig. 1a) .
As for the chemically induced nephroblastomas, bcatenin expression was heterogeneous and mostly involved tumor regions focally. In the present study, 12 of 24 (50%) rat nephroblastomas showed strong cytosolic bcatenin immunoreactivity, and this was mostly due to the very strong staining of the blastematous subcompartment in these tumors (Fig. 1b) . Nuclear staining of b-catenin, although found only in focal areas within a given tumor, was observed in addition to membranous and cytosolic localization in 18 of 24 (75%) tumors analyzed and in 12 of 17 (71%) primary and 6 of 7 (86%) transplanted tumors, respectively.
As has been found in Wilms tumors [35] , nuclear bcatenin staining was not observed in every histologic subcompartment of a tumor when it showed nuclear accumulation in one compartment. Epithelial compartments that mimic normal tubular architecture showed a prominent membranous staining (Fig. 1c) . Nuclear b-catenin expression, however, was observed in epithelial tumor compartments in 2 cases (Fig. 1d) . Cells of blastematous appearance showed mostly a membranous and cytosolic staining (Fig. 1e) , but some tumors displayed nuclear positivity as well (Fig. 1f) . The most frequently found nuclear immunoreactivity was, however, in cells with mesenchymal differentiation, such as spindle or rhabdomyoblastoid cells. Although a few mesenchymal tumor subcompartments were without any nuclear b-catenin immunoreactivity (Fig. 1g) , the percentage of nuclear-positive cells in mesenchymal/ stromal areas (Fig. 1h) sometimes ranged up to 80%. Similarly, a strong cytosolic staining was observed in mesenchymal subcompartments (not shown). The immunohistochemical results are summarized in Table 1 .
TOPflash/FOPflash reporter assays Wnt signaling activity can be measured in vitro with the TOPflash/FOPflash reporter assay [36] . The TOPflash plasmid contains a luciferase reporter gene that is under the control of multimerized TCF/b-catenin binding sites. Active nuclear b-catenin, if present, would bind to and transactivate this reporter. The FOPflash plasmid, however, contains mutant instead of normal TCF recognition sites, to which TCF/b-catenin complexes cannot bind. In order to assay wnt signaling activity in rat nephroblastoma cells, we used the ENU-T1 cell line, which was derived from an ENU-induced rat nephroblastoma by Nagashima and colleagues [30] . As shown in Figure 2 , ENU-T1 cells showed lower activation of wnt signaling (TOPflash/FOPflash ratio 1.52 (SD 0.47)) than 293T cells [32] , which are known to have a low intrinsic wnt activity (TOPflash/FOPflash ratio 1.71 (SD 0.22)), whereas HCT116 cells, a human colorectal cancer cell line harboring an oncogenic mutation of b-catenin [31] , showed a 10-fold higher expression of TOPflash than of FOPflash (TOPflash/FOPflash ratio 10.21 (SD 0.79)). These findings do not support the idea that wnt signaling is significantly activated in ENU-T1 cells.
Finally, genomic DNA from all tumors and from ENU-T1 cells was analyzed for mutations in exon 3 of the b-catenin gene Ctnnb1 by sequencing analysis. In 15 cases from which no frozen material was available, genomic DNA was extracted from paraffin-embedded, hematoxylin and eosin-stained tissue after microdissection to remove contaminating normal kidney tissue.
For sequence analysis of the region encoding the regulatory phosphorylation sites within the amino terminus of the b-catenin protein, exon 3 of Ctnnb1 was amplified by PCR and amplification products were subjected to direct sequencing. However, in 24 of 24 samples analyzed we did not find a single mutation. As a positive control, CC531 cells were analyzed, which harbor a known mutation in codon 41 (ACCRATC) of Ctnnb1 [37] . This mutation was clearly identified in our study (not shown).
We also screened the zinc-finger region of WT1 for mutations by amplifying exons 7-10 of the WT1 gene. Sequence analysis, however, did not reveal any mutation. The results of the sequencing analysis are included in Table 1 .
DISCUSSION
Aberrant activation of the wnt signaling pathway results in stabilization and nuclear accumulation of b-catenin protein. This phenomenon has been recognized as an important oncogenic step in various human tumor entities. Because of its widespread involvement in human cancer, the wnt signaling pathway has become a major focus of novel targeted therapeutic strategies. Because a significant proportion of Wilms tumors bear mutations of CTNNB1 [9, 10] or show an otherwise activated wnt signaling pathway [35, 38] , any such novel targeted therapy may turn out to have an effect on Wilms tumor patients. To test the efficacy of novel therapies, however, appropriate preclinical model systems are required. In the present study, we have analyzed the only currently available animal model of Wilms tumors, chemically induced rat nephroblastomas, for alterations in the wnt signaling pathway similar to those that have been found in human Wilms tumors.
Using immunohistochemistry, we found that bcatenin protein in normal rat kidney was mainly localized to the tubular epithelial membranes, starting from the epithelium of the Bowman's capsule down to the collecting duct. These findings probably reflect the important role of b-catenin in cell-cell adhesion and are in accordance with what is known about b-catenin expression in normal human kidney. The stronger staining we observed in the distal tubules may reflect the fact that there are considerably more intercellular junctions in the distal tubules. The analyzed sections of normal rat kidney never showed b-catenin staining of nonepithelial components, such as capillary loops or stroma, and no nuclear bcatenin staining was ever observed in normal rat kidney cells. When analyzing chemically induced rat nephroblastomas, however, we found 18 of 24 (75%) tumors with pronounced nuclear accumulation of b-catenin protein. Previously, 24 of 36 (66%) human Wilms tumors have been reported to show exactly the same phenomenon [35] . We conclude from these findings that activation of Mainly blastemal or mesenchymal rat nephroblastoma cells (although always only a subset of these) showed nuclear accumulation of b-catenin protein. Only rarely did epithelial subcompartments also show nuclear localization of b-catenin. This is very similar to the human situation, that is, nuclear positivity in epithelial-like tumor cells has been reported in only a single case [35] .
The intratumoral heterogeneity in nuclear b-catenin immunoreactivity is intriguing. It is, however, unlikely the cause was technical. Normal rat kidney tissue never showed nuclear localization and was often present on the same section as the tumor that showed nuclear b-catenin. Intratumoral heterogeneity in immunostaining has also been described in a variety of human malignancies [35, [39] [40] [41] . In Wilms tumors, genetic heterogeneity has been previously ruled out as an alternative explanation for the observed heterogeneity in nuclear immunoreactivity by showing that regions lacking nuclear b-catenin accumulation had the same mutational state as regions with nuclear b-catenin positivity [35] . From these former studies, it is apparent that mutational activation of the wnt signaling pathway is required but not sufficient on its own for nuclear accumulation of b-catenin protein and that other, epigenetic factors are likely to contribute to this phenomenon.
Although the immunohistochemical findings on bcatenin protein expression and intracellular distribution in rat nephroblastomas are well in accordance with previous studies in Wilms tumors, it was surprising that we did not find any mutation in Ctnnb1 or WT1. Because we used a rat colon cancer cell line, CC531, as a control we can exclude technical difficulties as being responsible for the failure of detecting any mutation. CC531 cells harbor a known mutation in codon 41 of Ctnnb1 (ACCRATC) [37] , and this mutation was readily confirmed in the present study. Tumor DNA, however, could have been contaminated by DNA from normal adjacent tissue present in the samples used here. To exclude this, in 15 cases we used DNA extracted from tumor tissue obtained after microdissection, but we found no mutation in these cases either. We conclude that activation of the wnt signaling pathway in rat nephroblastomas occurs through mutations of other members of the wnt signaling pathway, which may include AXIN-2, GSK-3b, TCF-4, or APC [42] or through mutations in genes like WTX, which then indirectly lead to constitutive wnt signaling [11, 43] . As an important member of the b-catenin-destruction complex, WTX supports ubiquitinylation and degradation of the bcatenin protein and therefore prevents b-catenin localization in the nucleus. Inactivating mutations of WTX have been found in about one third of human Wilms tumors and could explain a high proportion of tumors showing nuclear b-catenin protein in the absence of CTNNB1 or WT1 mutations. Similarly, rat WTX might be involved in the pathogenesis of rat nephroblastomas, although no studies have yet been carried out to address this issue.
We also assayed a cell line derived from ENU-treated rats, ENU-T1, by the TOPflash/FOPflash reporter gene assay. This assay is well suited to detect any activation of the wnt signaling pathway irrespective of which exact member of the wnt signaling cascade is activated. However, it can do so only in cultured cells. Unfortunately, ENU-T1 represents the only one established cell line derived from a chemically induced rat nephroblastoma, and these cells showed weak but not significant activation of wnt signaling pathway activity in our assays.
In conclusion, our findings of nuclear b-catenin protein found in the majority of tumors indicate that activation of the wnt signaling pathway plays a significant role in the development of chemically induced rat nephroblastomas. This activation appears, however, to be independent of Ctnnb1 and WT1 mutations. Chemically induced rat nephroblastomas may still provide a valuable platform for future preclinical studies targeting the wnt signaling pathway. 
